Currently, there are no salt forms of this compound available.
Przejdź do
T144
(±)-Thalidomide
≥98%, beta-secretase inhibitor, powder
Synonim(y):
(±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
| Gabaryty przesyłki | SKU | Dostępność | Cena netto |
|---|---|---|---|
| 100 mg | Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności | 579,00 zł | |
| 1 g | Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności | 3770,00 zł |
Informacje o tej pozycji
Wzór empiryczny (zapis Hilla):
C13H10N2O4
Numer CAS:
Masa cząsteczkowa:
258.23
UNSPSC Code:
12352111
eCl@ss:
39180303
PubChem Substance ID:
NACRES:
NA.77
EC Number:
200-031-1
MDL number:
579,00 zł
Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócNazwa produktu
(±)-Thalidomide, ≥98%, powder
ligand
thalidomide
Quality Level
assay
≥98%
form
powder
reaction suitability
reagent type: ligand
color
white
solubility
DMSO: 20 mg/mL, clear
originator
Celgene
SMILES string
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
1 of 1
Ta pozycja | |||
|---|---|---|---|
| form powder | form powder | form powder | form solid |
| assay ≥98% | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay >98% |
| Quality Level 200 | Quality Level 200 | Quality Level - | Quality Level - |
| originator Celgene | originator Celgene | originator - | originator Celgene |
| solubility DMSO: 20 mg/mL, clear | solubility DMSO: 15 mg/mL, clear | solubility DMSO: 2 mg/mL, clear | solubility DMSO: soluble, H2O: insoluble, ethanol: insoluble |
| color white | color white to beige | color white to beige | color white |
Application
Thalidomide has been used to study its neuropathological effects in mouse models of Alzheimer′s disease (AD). This study reported that long term administration of thalidomide causes beta-secretase inhibition and subsequently alleviates amyloid-like pathology[1]. Furthermore, thalidomide has also been used to evaluate its teratogenic functions. Thalidomide was found to affect endodermal differentiation and neural development in differentiating human embryonic and induced pluripotent stem cells[2].
Biochem/physiol Actions
(±)-Thalidomide selectively inhibits biosynthesis of tumor necrosis factor α (TNF-α). It also functions as an inhibitor of angiogenesis, an immunosuppressive agent, a sedative and a teratogen. Furthermore, thalidomide is known to exhibit antitumor functions in refractory multiple myeloma[3].
Features and Benefits
This compound was developed by Celgene. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Preparation Note
Thalidomide is soluble in DMSO at a concentration that is more than 20 mg/ml. It is insoluble in water and ethanol.
Ta strona może zawierać tekst przetłumaczony maszynowo.
related product
Numer produktu
Opis
Cennik
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A
Klasa składowania
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Yoav Mayshar et al.
Journal of cellular and molecular medicine, 15(6), 1393-1401 (2010-06-22)
Teratogens are substances that may cause defects in normal embryonic development while not necessarily being toxic in adults. Identification of possible teratogenic compounds has been historically beset by the species-specific nature of the teratogen response. To examine teratogenic effects on
Marzia Lazzerini et al.
JAMA, 310(20), 2164-2173 (2013-11-28)
Pediatric-onset Crohn disease is more aggressive than adult-onset disease, has high rates of resistance to existing drugs, and can lead to permanent impairments. Few trials have evaluated new drugs for refractory Crohn disease in children. To determine whether thalidomide is
S Singhal et al.
The New England journal of medicine, 341(21), 1565-1571 (1999-11-24)
Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease. Eighty-four previously
Karin Lauschke et al.
Archives of toxicology, 95(5), 1659-1670 (2021-03-05)
To test large numbers of chemicals for developmental toxicity, rapid in vitro tests with standardized readouts for automated data acquisition are needed. However, the most widely used assay, the embryonic stem cell test, relies on the counting of beating embryoid
Tomomi Noguchi et al.
Bioorganic & medicinal chemistry letters, 15(24), 5509-5513 (2005-09-27)
5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses
Produkty
Effective in key synthesis reactions like Knoevenagel condensation, thalidomide synthesis, and Suzuki coupling for sustainable chemical transformations.
Numer pozycji handlu globalnego
| SKU | NUMER GTIN |
|---|---|
| T144-1G | 04061826739945 |
| T144-100MG | 04061837337475 |
-
해당 제품 salt form 이 어떻게 되나요?
1 answer-
Helpful?
-
Active Filters
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej